Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 86

1.

RSV prevention and treatment in pediatric lung transplant patients: a survey of current practices among the International Pediatric Lung Transplant Collaborative.

Danziger-Isakov LA, Arslan D, Sweet S, Benden C, Goldfarb S, Wong J.

Pediatr Transplant. 2012 Sep;16(6):638-44. doi: 10.1111/j.1399-3046.2012.01744.x. Epub 2012 Jun 28.

PMID:
22738242
2.

Intravenous palivizumab and ribavirin combination for respiratory syncytial virus disease in high-risk pediatric patients.

Chávez-Bueno S, Mejías A, Merryman RA, Ahmad N, Jafri HS, Ramilo O.

Pediatr Infect Dis J. 2007 Dec;26(12):1089-93.

PMID:
18043443
3.

A multi-drug regimen for respiratory syncytial virus and parainfluenza virus infections in adult lung and heart-lung transplant recipients.

Liu V, Dhillon GS, Weill D.

Transpl Infect Dis. 2010 Feb;12(1):38-44. doi: 10.1111/j.1399-3062.2009.00453.x. Epub 2009 Sep 15.

PMID:
19761558
4.

Respiratory syncytial virus prophylaxis: a survey of pediatric solid organ transplant centers.

Michaels MG, Fonseca-Aten M, Green M, Charsha-May D, Friedman B, Seikaly M, Sánchez PJ.

Pediatr Transplant. 2009 Jun;13(4):451-6. doi: 10.1111/j.1399-3046.2008.01017.x. Epub 2008 Sep 10.

PMID:
18785906
5.

Oral versus inhaled ribavirin therapy for respiratory syncytial virus infection after lung transplantation.

Li L, Avery R, Budev M, Mossad S, Danziger-Isakov L.

J Heart Lung Transplant. 2012 Aug;31(8):839-44. doi: 10.1016/j.healun.2012.04.002. Epub 2012 May 22.

PMID:
22621746
6.

Detection, control, and management of a respiratory syncytial virus outbreak in a pediatric hematology-oncology department.

Shachor-Meyouhas Y, Zaidman I, Kra-Oz Z, Arad-Cohen N, Kassis I.

J Pediatr Hematol Oncol. 2013 Mar;35(2):124-8. doi: 10.1097/MPH.0b013e3182756edc.

PMID:
23128340
7.
8.

Prophylaxis in RSV infection (Palivizumab)--is it worthwhile?

Hashmi NA, Cosgrove JF, MacMahon P.

Ir Med J. 2000 Dec;93(9):284.

PMID:
11209917
9.

Low incidence of severe respiratory syncytial virus infections in lung transplant recipients despite the absence of specific therapy.

Uçkay I, Gasche-Soccal PM, Kaiser L, Stern R, Mazza-Stalder J, Aubert JD, van Delden C.

J Heart Lung Transplant. 2010 Mar;29(3):299-305. doi: 10.1016/j.healun.2009.08.012. Epub 2009 Oct 17.

PMID:
19837611
10.

Intravenous ribavirin is a safe and cost-effective treatment for respiratory syncytial virus infection after lung transplantation.

Glanville AR, Scott AI, Morton JM, Aboyoun CL, Plit ML, Carter IW, Malouf MA.

J Heart Lung Transplant. 2005 Dec;24(12):2114-9. Epub 2005 Sep 6.

PMID:
16364859
11.

Palivizumab for respiratory syncytial virus prophylaxis.

Sandritter T.

J Pediatr Health Care. 1999 Jul-Aug;13(4):191-5; quiz 196-7. Review.

PMID:
10690084
12.

Current practices for treatment of respiratory syncytial virus and other non-influenza respiratory viruses in high-risk patient populations: a survey of institutions in the Midwestern Respiratory Virus Collaborative.

Beaird OE, Freifeld A, Ison MG, Lawrence SJ, Theodoropoulos N, Clark NM, Razonable RR, Alangaden G, Miller R, Smith J, Young JA, Hawkinson D, Pursell K, Kaul DR.

Transpl Infect Dis. 2016 Apr;18(2):210-5. doi: 10.1111/tid.12510. Epub 2016 Mar 29.

PMID:
26923867
13.

Respiratory syncytial virus lower respiratory tract infection in a pediatric liver transplant recipient treated with oral ribavirin.

Keck M, Mindru C, Kalil AC, Mercer DF, Florescu DF.

Pediatr Transplant. 2012 Dec;16(8):E348-51. doi: 10.1111/j.1399-3046.2012.01700.x. Epub 2012 Apr 26.

PMID:
22533837
14.
15.

Use of palivizumab in infants and young children with severe respiratory disease: a Delphi study.

Gaboli M, de la Cruz ÒA, de Agüero MI, Moreno-Galdó A, Pérez GP, de Querol MS.

Pediatr Pulmonol. 2014 May;49(5):490-502. doi: 10.1002/ppul.22826. Epub 2013 Jun 18.

PMID:
23775884
16.

Clinical features and outcomes of paramyxoviral infection in lung transplant recipients treated with ribavirin.

McCurdy LH, Milstone A, Dummer S.

J Heart Lung Transplant. 2003 Jul;22(7):745-53.

PMID:
12873542
17.

Prophylaxis against respiratory syncytial virus in young children with cystic fibrosis.

Giebels K, Marcotte JE, Podoba J, Rousseau C, Denis MH, Fauvel V, Laberge S.

Pediatr Pulmonol. 2008 Feb;43(2):169-74.

PMID:
18085710
18.

Prophylaxis and treatment of respiratory syncytial virus in adult immunocompromised patients.

Hynicka LM, Ensor CR.

Ann Pharmacother. 2012 Apr;46(4):558-66. doi: 10.1345/aph.1Q553. Epub 2012 Mar 6. Review.

PMID:
22395247
19.

Palivizumab outcomes registry data from Spain: Infección Respiratoria Infantil por Virus Respiratorio Sincitial (IRIS) Study Group.

Carbonell-Estrany X.

Pediatr Infect Dis J. 2003 Feb;22(2 Suppl):S55-7; discussion S57.

PMID:
12671453
20.

Characteristics and outcome of respiratory syncytial virus infection in patients with leukemia.

Torres HA, Aguilera EA, Mattiuzzi GN, Cabanillas ME, Rohatgi N, Sepulveda CA, Kantarjian HM, Jiang Y, Safdar A, Raad II, Chemaly RF.

Haematologica. 2007 Sep;92(9):1216-23. Epub 2007 Aug 1.

Supplemental Content

Support Center